A Clinical Trial to assess the effect of Varunadi Vati in Medodushti w.s.r. to Dyslipidemia

A Randomized controlled clinical study to assess the effect Of Varunadi Vati in management of Medodushti with special reference to Dyslipidemia - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069018

Enrollment

Registered

2024-06-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria – Both Genders. Age group having 30 to 70 years age. Obese Dyslipidemic and Non-Obese Dyslipidemic Patients (BMI-18.50 to 40.00 kg/m2 as per New Updated WHO classification of BMI of 2004). Patient having Serum Total Cholesterol Level =200mg/dl Patient having Serum LDL Cholesterol Level =130mg/dl Patient having serum VLDL Cholesterol Level =40 mg/dl Patient having Serum HDL Cholesterol Level =40mg/dl Patient having Serum Triglyceride Level =150mg/dl

Exclusion criteria

Exclusion criteria: Exclusion Criteria- Pregnant and lactating mothers. Patients having Diabetes Mellitus. Patients having history of Respiratory Diseases Complications, Coronary Heart Diseases, Renal Diseases etc. Patients having Acute Complications like Severe Hypertension (B.P 150/90 mm Hg in those with age 60 and older, and 140/90 mm Hg for adults less than 60 yrs. According to Eighth Joint National Committee Guideline), Hepatitis or with history of major surgery etc. Patients having disorders like Carcinoma anywhere in the body etc.

Design outcomes

Primary

Measure	Time frame
To assess the effect of “Varunadi Vati ? on Lipid Levels (Lipid Profile) in Dyslipidemia.Timepoint: 8 weeks Follow up: Screening of patients clinically every week and Lipid Profile repeated every month (i.e every 4 weeks)	—

Secondary

Measure	Time frame
To observe the effect of ‘Varunadi Vati’ in comparison with Tab. Atorvastatin on Lipid Profile in patients of Dyslipidemia over a period of 8 weeks. Timepoint: 8 weeks Follow up: Screening of patients clinically every week & Lipid Profile repeated every month (i.e every 4 weeks)	—

Countries

India

Contacts

Public ContactAkanksha Vijay Agale

R. A. Podar Medical College (Govt.) (Ayu)

geeta.parulkar@gmail.com08652694332

Outcome results